Keyword: Abbott Laboratories

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

With scrutiny stateside mounting on the opioid industry, makers of the controversial drugs are looking to India as a new market.

J&J, Merck, Pfizer and Abbott reaped a combined $7 billion in savings from two tax reform provisions, and they spent most of it on investor payouts.

Why didn't Mylan CEO Heather Bresch back down on EpiPen price hikes? To change the subject, she tells CNN. And change it she did—for all of pharma

Newly bulked up by M&A, Mylan plans to cut a chunk of its workforce—perhaps up to 3,500 jobs—as it moves to retrench and refocus.

Abbott picked up Vietnamese drug manufacturer Glomed for an undisclosed price in a deal that gives the pharma giant two manufacturing facilities in that country in addition to expanding its visibility in Southeast Asia.

Abbott has taken a breather for now on possible M&A activity of generic companies in emerging markets as price multiples are too steep.